International Journal of Bipolar Disorders (May 2024)

Integrated proteomic and genomic analysis to identify predictive biomarkers for valproate response in bipolar disorder: a 6-month follow-up study

  • Hyunju Lee,
  • Dohyun Han,
  • Kyung Sue Hong,
  • Kyooseob Ha,
  • Hyeyoon Kim,
  • Eun Young Cho,
  • Woojae Myung,
  • Sang Jin Rhee,
  • Jayoun Kim,
  • Tae Hyon Ha,
  • Kang Eun Lee,
  • Hye Won Jung,
  • Yejin Lee,
  • Dongbin Lee,
  • Hyeona Yu,
  • Daseul Lee,
  • Yun Seong Park,
  • Yong Min Ahn,
  • Ji Hyun Baek,
  • Se Hyun Kim

DOI
https://doi.org/10.1186/s40345-024-00342-x
Journal volume & issue
Vol. 12, no. 1
pp. 1 – 10

Abstract

Read online

Abstract Background Several genetic studies have been undertaken to elucidate the intricate interplay between genetics and drug responses in bipolar disorder (BD). However, there has been notably limited research on biomarkers specifically linked to valproate, with only a few studies investigating integrated proteomic and genomic factors in response to valproate treatment. Therefore, this study aimed to identify biological markers for the therapeutic response to valproate treatment in BD. Patients with BD in remission were assessed only at baseline, whereas those experiencing acute mood episodes were evaluated at three points (baseline, 8 ± 2 weeks, and 6 ± 1 months). The response to valproate treatment was measured using the Alda scale, with individuals scoring an Alda A score ≥ 5 categorized into the acute-valproate responder (acute-VPAR) group. We analyzed 158 peptides (92 proteins) from peripheral blood samples using multiple reaction monitoring mass spectrometry, and proteomic result-guided candidate gene association analyses, with 1,627 single nucleotide variants (SNVs), were performed using the Korean chip. Results The markers of 37 peptides (27 protein) showed temporal upregulation, indicating possible association with response to valproate treatment. A total of 58 SNVs in 22 genes and 37 SNVs in 16 genes showed nominally significant associations with the Alda A continuous score and the acute-VPAR group, respectively. No SNVs reached the genome-wide significance threshold; however, three SNVs (rs115788299, rs11563197, and rs117669164) in the secreted phosphoprotein 2 gene reached a gene-based false discovery rate-corrected significance threshold with response to valproate treatment. Significant markers were associated with the pathophysiological processes of bipolar disorders, including the immune response, acute phase reaction, and coagulation cascade. These results suggest that valproate effectively suppresses mechanisms associated with disease progression. Conclusions The markers identified in this study could be valuable indicators of the underlying mechanisms associated with response to valproate treatment.

Keywords